Roche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.
Dive Brief:
Roche has agreed to acquire PathAI, a Boston-based digital pathology firm, for up to $1.05 billion.
Roche plans to pay $750 million upfront and up to $300 million in additional milestone payments, according to a Thursday announcement.
The acquisition is expected to close in the second half of 2026, subject to customary closing conditions, including antitrust and regulatory approvals.
Dive Insight:
Immunai expands AstraZeneca collaboration in deal worth up to $37.5 million
Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
Anthropic approaches $1 trillion valuation as revenue grows fivefold
UCB to acquire maker of antibody treatments for autoimmune diseases
Torch CEO Ilya Abyzov previously co-founded Forward, a direct-to-consumer primary care business that did patient visits with…
Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease…
U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered…
New York-based AI biotech firm says AstraZeneca will keep using its AMICA-OS platform for oncology drug development under…
US company is attempting to acquire the maker of a new treatment for pancreatic cancer
L’intesa prevede il pagamento agli azionisti della biotech di 129 dollari per azione, con un premio del 27% rispetto al prezzo di…
